Evonik Expands Capacity in Germany
CMO Evonik begins capacity expansion of APIs and intermediates at its sites in Dossenheim and Hanau Germany to increase EU supply security for drug products.
Evonik began the first stage of a 25 million Euros (more than US$27 million) long-term program to expand the capacity of its Dossenheim and Hanau facilities in Germany, the company announced in a May 5, 2020 press release. The company says the capacity will support growing demand for the contract manufacturing of APIs and advanced intermediates in Europe.
“The COVID-19 pandemic has amplified the focus of many pharmaceutical companies to have European-based manufacturing sites that can support the production of their life-saving drug products for reliable supply to regional healthcare markets,” said Thomas Riermeier, senior vice-president of Evonik’s Health Care business line, in the press release. “The expansion of our Dossenheim and Hanau sites in Germany is now underway to support customers seeking a trusted European site for the clinical and commercial production of their APIs and intermediates.”
“In addition to increasing our production capacity for APIs and advanced intermediates within Europe, the expansion of the two multi-purpose cGMP sites in Dossenheim and Hanau, Germany will widen Evonik’s ability to support highly complex customer projects,” said Dr. Andreas Meudt, vice-president of Exclusive Synthesis for the Health Care business line of Evonik.
The APIs that will be produced at the sites typically require a range of advanced technologies including continuous processing, highly pure polyethylene glycols (PEGs) and methoxy-PEGs, catalysis, and cryogenic chemistry. The first stage of the project is scheduled to be completed by the middle of 2021, and the project should be completed by 2024.
Source: Evonik
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
